Strategies to manage hepatitis C virus infection disease burden - volume 3.

Clicks: 529
ID: 55096
2015
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Popular

Ranked #2 of 14 articles by views in journal of viral hepatitis

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
The hepatitis C virus (HCV) epidemic was forecasted through 2030 for 15 countries in Europe, the Middle East and Asia, and the relative impact of two scenarios was considered: increased treatment efficacy while holding the annual number of treated patients constant and increased treatment efficacy and an increased annual number of treated patients. Increasing levels of diagnosis and treatment, in combination with improved treatment efficacy, were critical for achieving substantial reductions in disease burden. A 90% reduction in total HCV infections within 15 years is feasible in most countries studied, but it required a coordinated effort to introduce harm reduction programmes to reduce new infections, screening to identify those already infected and treatment with high cure rate therapies. This suggests that increased capacity for screening and treatment will be critical in many countries. Birth cohort screening is a helpful tool for maximizing resources. Among European countries, the majority of patients were born between 1940 and 1985. A wider range of birth cohorts was seen in the Middle East and Asia (between 1925 and 1995).
Reference Key
alfaleh2015strategiesjournal Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Alfaleh, F Z;Nugrahini, N;Matičič, M;Tolmane, I;Alzaabi, M;Hajarizadeh, B;Valantinas, J;Kim, D Y;Hunyady, B;Abaalkhail, F;Abbas, Z;Abdou, A;Abourached, A;Al Braiki, F;Al Hosani, F;Al Jaberi, K;Al Khatry, M;Al Mulla, M A;Al Quraishi, H;Al Rifai, A;Al Serkal, Y;Alam, A;Alashgar, H I;Alavian, S M;Alawadhi, S;Al-Dabal, L;Aldins, P;Alghamdi, A S;Al-Hakeem, R;Aljumah, A A;Almessabi, A;Alqutub, A N;Alswat, K A;Altraif, I;Andrea, N;Assiri, A M;Babatin, M A;Baqir, A;Barakat, M T;Bergmann, O M;Bizri, A R;Chaudhry, A;Choi, M S;Diab, T;Djauzi, S;El Hassan, E S;El Khoury, S;Estes, C;Fakhry, S;Farooqi, J I;Fridjonsdottir, H;Gani, R A;Ghafoor Khan, A;Gheorghe, L;Goldis, A;Gottfredsson, M;Gregorcic, S;Gunter, J;Hamid, S;Han, K H;Hasan, I;Hashim, A;Horvath, G;Husni, R;Jafri, W;Jeruma, A;Jonasson, J G;Karlsdottir, B;Kim, Y S;Koutoubi, Z;Lesmana, L A;Liakina, V;Lim, Y S;Löve, A;Maimets, M;Makara, M;Malekzadeh, R;Memon, M S;Merat, S;Mokhbat, J E;Mourad, F H;Muljono, D H;Nawaz, A;Olafsson, S;Priohutomo, S;Qureshi, H;Rassam, P;Razavi, H;Razavi-Shearer, D;Razavi-Shearer, K;Rozentale, B;Sadik, M;Saeed, K;Salamat, A;Salupere, R;Sanai, F M;Sanityoso Sulaiman, A;Sayegh, R A;Schmelzer, J D;Sharara, A I;Sibley, A;Siddiq, M;Siddiqui, A M;Sigmundsdottir, G;Sigurdardottir, B;Speiciene, D;Sulaiman, A;Sultan, M A;Taha, M;Tanaka, J;Tarifi, H;Tayyab, G;Ud Din, M;Umar, M;Videčnik-Zorman, J;Yaghi, C;Yunihastuti, E;Yusuf, M A;Zuberi, B F;Blach, S;
Journal journal of viral hepatitis
Year 2015
DOI
10.1111/jvh.12474
URL
Keywords
prevalence Epidemiology mortality treatment hepatitis c diagnosis incidence hepatitis c virus disease burden strategy elimination scenarios

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.